# NovaBridge Biosciences: Form 20-F for the period ended Dec 31, 2023

- Company: [NovaBridge Biosciences](/companies/nbp.md) (CIK 1778016)
- Form: 20-F
- Filed: 2024-04-30
- Accepted by EDGAR: Apr 30, 2024, 07:01 ET
- Period: 2023-12-31
- Accession: 0001104659-24-054452
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1778016/000110465924054452/imab-20231231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1778016/000110465924054452/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $3.9m | us-gaap:Revenues |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $114.2m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months, 2023-01-01 to 2023-12-31 | $102.0k | us-gaap:InterestExpense |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$206.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | −$1.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | −$1.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 191,423,850 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$183.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-12-31 | $301.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $329.1m | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $368.0m | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $58.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $126.0m | us-gaap:Liabilities |
| Short-term borrowings | at 2023-12-31 | $4.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2023-12-31 | $242.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2023-12-31 | 185,613,662 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1778016/000110465924054452/imab-20231231x20f.htm

Filed Apr 30, 2024.
Source: SEC EDGAR, the filing index for accession 0001104659-24-054452. Last ingested by Listed: Nov 6, 2026, 02:19 ET. No prices; not investment advice.